Key result
PDE5 inhibitors may improve pediatric COVID-19-induced pulmonary hypertension by reducing inflammation and improving blood flow.
Why the study?
The interaction between COVID-19 and pulmonary hypertension in children is not widely known.
Does the use of phosphodiesterase-5 inhibitors improve outcomes in children with COVID-19-induced pulmonary hypertension?
Does the use of phosphodiesterase-5 inhibitors improve outcomes in children with COVID-19-induced pulmonary hypertension?
Phosphodiesterase-5 inhibitors like sildenafil represent a potential therapeutic option for managing COVID-19-induced pulmonary hypertension in children due to their vasodilatory and anti-inflammatory properties.
Should not yet change practice for pediatric COVID-19 PH; leaves open PDE-5 inhibitor role pending controlled trials.
Respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first occurred in Wuhan, China, in December 2019 and was declared as a pandemic by WHO. The interaction between the 2019 coronavirus disease (COVID-19) and pulmonary hypertension (PH) in children is not widely known. Phosphodiesterase-5 inhibitors (PDEI), one class of drugs used to treat PH, including sildenafil, can suppress angiotensin type I (AT-1) receptor expression. Furthermore, it reduces proinflammatory cytokines and infiltrates the alveolar, inhibits endothelial and smooth muscle transition, mesenchymal cells in the pulmonary artery, and prevents clotting and thrombosis complications. Sildenafil has shown positive effects by diverting the blood flow to the lungs in such a way that ventilation is adequate and can also be anti-inflammatory.
No takes yet. Share an insight, caveat, or question.
Dimiati et al. (2022) conducted a review in COVID-19-induced pulmonary hypertension. Phosphodiesterase-5 inhibitors (sildenafil) was evaluated. Phosphodiesterase-5 inhibitors, including sildenafil, may provide therapeutic benefits for COVID-19-induced pulmonary hypertension in children by reducing inflammation and improving pulmonary blood flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: